Items per page
Sort by

Send to:

Choose Destination

Results: 6

Cited In for PubMed (Select 17107250)


Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia.

Hatta K, Ito H.

Clin Psychopharmacol Neurosci. 2014 Apr;12(1):1-7. doi: 10.9758/cpn.2014.12.1.1. Epub 2014 Apr 24. Review.


An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia.

Hirano J, Watanabe K, Suzuki T, Uchida H, Den R, Kishimoto T, Nagasawa T, Tomita Y, Hara K, Ochi H, Kobayashi Y, Ishii M, Fujita A, Kanai Y, Goto M, Hayashi H, Inamura K, Ooshima F, Sumida M, Ozawa T, Sekigawa K, Nagaoka M, Yoshimura K, Konishi M, Inagaki A, Saito T, Motohashi N, Mimura M, Okubo Y, Kato M.

Neuropsychiatr Dis Treat. 2013;9:1553-64. doi: 10.2147/NDT.S46108. Epub 2013 Oct 11.


Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.

Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM.

Neuropsychopharmacology. 2010 Jan;35(2):581-90. doi: 10.1038/npp.2009.164. Epub .


Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.

Faries DE, Nyhuis AW, Ascher-Svanum H.

Cost Eff Resour Alloc. 2009 May 27;7:11. doi: 10.1186/1478-7547-7-11.


Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.

Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ.

BMC Med. 2008 Jun 30;6:17. doi: 10.1186/1741-7015-6-17.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk